Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 14 05 2019
accepted: 15 03 2020
entrez: 8 4 2020
pubmed: 8 4 2020
medline: 9 7 2020
Statut: epublish

Résumé

Retaining patients starting antiretroviral therapy (ART) and ensuring good adherence remain cornerstone of long-term viral suppression. In this era of test and treat (T&T) policy, ensuring that patients starting ART remain connected to HIV clinics is key to achieve the UNAIDS 90-90-90 targets. Currently, limited studies have evaluated the effect of early ART initiation on loss to follow up in a routine health care delivery setting. We studied the cumulative incidence, incidence rate of loss to follow up (LTFU), and factors associated with LTFU in a primary healthcare clinic that has practiced T&T since 2012. We retrospectively analyzed extracted routine program data on patients who started ART from January 2012 to 4th July 2016. We defined LTFU as failure of a patient to return to the HIV clinic for at least 90 days from the date of their last appointment. We calculated cumulative incidence, incidence rate and fitted a multivariable Cox proportion hazards regression model to determine factors associated with LTFU. Of the 7,553 patients included in our sample, 3,231 (42.8%) started ART within seven days following HIV diagnosis. There were 1,180 cases of LTFU observed over 15,807.7 person years at risk. The overall incidence rate (IR) of LTFU was 7.5 (95% CI, 7.1-7.9) per 100 person years of observation (pyo). Cumulative incidence of LTFU increased with duration of follow up from 8.9% (95% CI, 8.2-9.6%) at 6 months to 20.2% (95% CI, 19.0-21.4%) at 48 months. Predictors of elevated risk of LTFU were: starting ART within 7 days following HIV diagnosis ((aHR) = 1.69, 95% CI, 1.50-1.91), lack of a telephone set (aHR = 1.52, 95% CI, 1.35-1.71), CD4 cell count of 200-350μ/ml (aHR = 1.21, 95% CI, 1.01-1.45) and baseline WHO clinical stage 3 or 4 (aHR = 1.35, 95% CI, 1.10-1.65). Factors associated with a reduced risk of LTFU were: baseline age ≥25 years (aHR ranging from 0.62, 95% CI, 0.47-0.81 for age group 25-29 years to 0.24, 95% CI, 0.13-0.44 for age group ≥50 years), at least primary education level (aHR ranging from aHR = 0.77, 95% CI, 0.62-0.94 for primary education level to 0.50, 95% CI, 0.34-0.75 for post-secondary education level), and having a BMI ≥ 30 (aHR = 0.28, 95% CI, 0.15-0.51). The risk of loss to follow up increased with time and was higher among patients who started ART within seven days following HIV diagnosis, higher among patients without a telephone set, lower among patients aged ≥ 25 years, lower among patients with at least primary education and lower among patients with BMI of ≥ 30. In this era of T&T, it will be important for HIV programs to initiate and continue enhanced therapeutic education programs that target high risk groups, as well as leveraging on mHealth to improve patients' retention on ART throughout the cascade of care.

Sections du résumé

BACKGROUND
Retaining patients starting antiretroviral therapy (ART) and ensuring good adherence remain cornerstone of long-term viral suppression. In this era of test and treat (T&T) policy, ensuring that patients starting ART remain connected to HIV clinics is key to achieve the UNAIDS 90-90-90 targets. Currently, limited studies have evaluated the effect of early ART initiation on loss to follow up in a routine health care delivery setting. We studied the cumulative incidence, incidence rate of loss to follow up (LTFU), and factors associated with LTFU in a primary healthcare clinic that has practiced T&T since 2012.
METHODS
We retrospectively analyzed extracted routine program data on patients who started ART from January 2012 to 4th July 2016. We defined LTFU as failure of a patient to return to the HIV clinic for at least 90 days from the date of their last appointment. We calculated cumulative incidence, incidence rate and fitted a multivariable Cox proportion hazards regression model to determine factors associated with LTFU.
RESULTS
Of the 7,553 patients included in our sample, 3,231 (42.8%) started ART within seven days following HIV diagnosis. There were 1,180 cases of LTFU observed over 15,807.7 person years at risk. The overall incidence rate (IR) of LTFU was 7.5 (95% CI, 7.1-7.9) per 100 person years of observation (pyo). Cumulative incidence of LTFU increased with duration of follow up from 8.9% (95% CI, 8.2-9.6%) at 6 months to 20.2% (95% CI, 19.0-21.4%) at 48 months. Predictors of elevated risk of LTFU were: starting ART within 7 days following HIV diagnosis ((aHR) = 1.69, 95% CI, 1.50-1.91), lack of a telephone set (aHR = 1.52, 95% CI, 1.35-1.71), CD4 cell count of 200-350μ/ml (aHR = 1.21, 95% CI, 1.01-1.45) and baseline WHO clinical stage 3 or 4 (aHR = 1.35, 95% CI, 1.10-1.65). Factors associated with a reduced risk of LTFU were: baseline age ≥25 years (aHR ranging from 0.62, 95% CI, 0.47-0.81 for age group 25-29 years to 0.24, 95% CI, 0.13-0.44 for age group ≥50 years), at least primary education level (aHR ranging from aHR = 0.77, 95% CI, 0.62-0.94 for primary education level to 0.50, 95% CI, 0.34-0.75 for post-secondary education level), and having a BMI ≥ 30 (aHR = 0.28, 95% CI, 0.15-0.51).
CONCLUSION
The risk of loss to follow up increased with time and was higher among patients who started ART within seven days following HIV diagnosis, higher among patients without a telephone set, lower among patients aged ≥ 25 years, lower among patients with at least primary education and lower among patients with BMI of ≥ 30. In this era of T&T, it will be important for HIV programs to initiate and continue enhanced therapeutic education programs that target high risk groups, as well as leveraging on mHealth to improve patients' retention on ART throughout the cascade of care.

Identifiants

pubmed: 32255796
doi: 10.1371/journal.pone.0217606
pii: PONE-D-19-13581
pmc: PMC7138304
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0217606

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

BMC Health Serv Res. 2015 Jul 04;15:259
pubmed: 26141729
PLoS Med. 2007 Oct 16;4(10):e298
pubmed: 17941716
BMC Public Health. 2018 May 2;18(1):583
pubmed: 29720146
PLoS One. 2009 Jun 04;4(6):e5790
pubmed: 19495419
J Int AIDS Soc. 2016 Mar 11;19(1):20672
pubmed: 26976377
Curr Opin HIV AIDS. 2012 Mar;7(2):99-105
pubmed: 22227585
Lancet Public Health. 2018 Mar;3(3):e143-e152
pubmed: 29361433
J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):555-562
pubmed: 28129256
Infect Dis Poverty. 2018 Apr 25;7(1):35
pubmed: 29690932
Lancet Infect Dis. 2014 Apr;14(4):281-90
pubmed: 24602844
AIDS. 2016 Nov 28;30(18):2855-2864
pubmed: 27603290
PLoS One. 2012;7(6):e39894
pubmed: 22761924
Glob Health Action. 2013 Sep 12;6:21682
pubmed: 24028937
PLoS One. 2019 Jan 30;14(1):e0210287
pubmed: 30699151
Int J Pediatr. 2016;2016:8487378
pubmed: 28127311
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e46-55
pubmed: 25692336
PLoS Med. 2017 Jul 25;14(7):e1002357
pubmed: 28742880
AIDS Res Ther. 2018 Nov 17;15(1):20
pubmed: 30445984
AIDS Res Ther. 2007 May 14;4:11
pubmed: 17502001
Clin Infect Dis. 2013 Nov;57(9):1343-50
pubmed: 23899683
BMJ Open. 2013 Oct 25;3(10):e003499
pubmed: 24163204
AIDS. 2014 Sep 24;28(15):2241-9
pubmed: 25022596
PLoS One. 2018 Jan 26;13(1):e0188488
pubmed: 29373574
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Lancet HIV. 2016 Apr;3(4):e175-82
pubmed: 27036993
HIV AIDS (Auckl). 2013;5:1-17
pubmed: 23326204
J Acquir Immune Defic Syndr. 2015 May 1;69(1):98-108
pubmed: 25942461
J Int AIDS Soc. 2019 Feb;22(2):e25239
pubmed: 30734510
PLoS One. 2015 Jun 26;10(6):e0130649
pubmed: 26114436
BMC Infect Dis. 2019 Jan 21;19(1):77
pubmed: 30665434
J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e15-e18
pubmed: 28394821
Lancet Infect Dis. 2005 Jun;5(6):361-73
pubmed: 15919622
PLoS One. 2013 Sep 24;8(9):e71557
pubmed: 24086252
J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):20027
pubmed: 25724512
BMC Infect Dis. 2018 Oct 24;18(1):533
pubmed: 30355356
Internet Interv. 2018 Jun 21;13:82-104
pubmed: 30206523

Auteurs

Julius Kiwanuka (J)

AIDS Healthcare Foundation, Kampala, Uganda.
Department of Epidemiology and Biostatistics, School of Public Health, Makerere University Kampala, Uganda.

Jacinta Mukulu Waila (J)

Department of Epidemiology and Biostatistics, School of Public Health, Makerere University Kampala, Uganda.

Methuselah Muhindo Kahungu (M)

AIDS Healthcare Foundation, Kampala, Uganda.
Department of Epidemiology and Biostatistics, School of Public Health, Makerere University Kampala, Uganda.

Jonathan Kitonsa (J)

Department of Epidemiology and Biostatistics, School of Public Health, Makerere University Kampala, Uganda.
Medical Research Council / Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.

Noah Kiwanuka (N)

Department of Epidemiology and Biostatistics, School of Public Health, Makerere University Kampala, Uganda.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH